152 related articles for article (PubMed ID: 20926021)
81. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
Shirai N; Furuta T; Xiao F; Kajimura M; Hanai H; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
[TBL] [Abstract][Full Text] [Related]
82. CYP2C19 polymorphism and proton pump inhibitors.
Klotz U; Schwab M; Treiber G
Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
[TBL] [Abstract][Full Text] [Related]
83. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Tamura T; Kurata M; Inoue S; Kondo T; Goto Y; Kamiya Y; Kawai S; Hamajima N
Nagoya J Med Sci; 2011 Feb; 73(1-2):25-31. PubMed ID: 21614934
[TBL] [Abstract][Full Text] [Related]
84. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.
Shimatani T; Inoue M; Kuroiwa T; Moriwaki M; Xu J; Ikawa K; Morikawa N; Tazuma S
Dig Dis Sci; 2007 Feb; 52(2):390-5. PubMed ID: 17211705
[TBL] [Abstract][Full Text] [Related]
85. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
86. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Pantoflickova D; Dorta G; Ravic M; Jornod P; Blum AL
Aliment Pharmacol Ther; 2003 Jun; 17(12):1507-14. PubMed ID: 12823153
[TBL] [Abstract][Full Text] [Related]
87. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.
Belhocine K; Vavasseur F; Volteau C; Flet L; Touchefeu Y; Bruley des Varannes S
BMC Gastroenterol; 2014 Jul; 14():128. PubMed ID: 25027286
[TBL] [Abstract][Full Text] [Related]
88. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Sugimoto M; Furuta T; Nakmura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
[No Abstract] [Full Text] [Related]
89. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Miyoshi M; Mizuno M; Ishiki K; Nagahara Y; Maga T; Torigoe T; Nasu J; Okada H; Yokota K; Oguma K; Tsuji T
J Gastroenterol Hepatol; 2001 Jul; 16(7):723-8. PubMed ID: 11446878
[TBL] [Abstract][Full Text] [Related]
90. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
91. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
92. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
[TBL] [Abstract][Full Text] [Related]
93. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
[TBL] [Abstract][Full Text] [Related]
94. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
95. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.
Wang Y; Yuan Y; Meng L; Fan H; Xu J; Zhang H; Wang M; Yuan H; Ou N; Zhang H; Chao Y; Shi R
Eur J Clin Pharmacol; 2011 Jan; 67(1):25-31. PubMed ID: 21110014
[TBL] [Abstract][Full Text] [Related]
96. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
97. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
Takahashi K; Yano I; Fukuhara Y; Katsura T; Takahashi T; Ito N; Yamamoto S; Ogawa O; Inui K
Drug Metab Pharmacokinet; 2007 Dec; 22(6):441-4. PubMed ID: 18159131
[TBL] [Abstract][Full Text] [Related]
98. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Saitoh T; Otsuka H; Kawasaki T; Endo H; Iga D; Tomimatsu M; Fukushima Y; Katsube T; Ogawa K; Otsuka K
Hepatogastroenterology; 2009; 56(91-92):703-6. PubMed ID: 19621685
[TBL] [Abstract][Full Text] [Related]
99. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
He XX; Zhao YH; Hao YT
Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
[TBL] [Abstract][Full Text] [Related]
100. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.
Hosohata K; Masuda S; Yonezawa A; Sugimoto M; Takada Y; Kaido T; Ogura Y; Oike F; Uemoto S; Inui K
Drug Metab Pharmacokinet; 2009; 24(5):458-63. PubMed ID: 19881258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
